Viewing nowCombinationDapagliflozin Metformin Controlled-Release Tablet 10/1000 mg
Dapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinpoong Pharmaceutical Co., Ltd.

MFDS item code 202300355 · Approved 2023.01.27 · Insurance code 648508130
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication helps in blood sugar control for adults with type 2 diabetes by combining dapagliflozin and metformin. It is used as an adjunct to diet and exercise for patients whose blood sugar is not well controlled, and may also be considered for those with type 2 diabetes who have cardiovascular disease or risk factors. For cardiovascular-related information, please refer to the healthcare professional's guide. Overall, this medication effectively improves blood sugar control in patients with type 2 diabetes.
The dose of this medicine should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior antidiabetic drug treatment for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior antidiabetic drug treatment, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient’s current dose of metformin or the nearest appropriate therapeutically equivalent dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. For patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue, such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. In patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who have no other condition that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, this medicine must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to be reduced in older adults, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).
This medication should not be administered to patients with impaired kidney function or serious infections, heart failure, etc. It may rarely cause a metabolic disorder known as lactic acidosis; therefore, kidney function should be routinely monitored, and healthcare professionals should be consulted immediately if any unusual symptoms occur. There is a risk of hypoglycemia when taken with insulin or sulfonylureas, so blood sugar levels should be closely monitored; dosage adjustments may be necessary. Patients with dehydration or low blood pressure should verify their hydration status and blood pressure before taking this medication and monitor for dizziness or hypotension symptoms during treatment. This medication may increase the risk of genitourinary infections; prompt treatment is necessary if any infection symptoms occur. Women who are pregnant or breastfeeding should not use this medication, and those planning for pregnancy or who may become pregnant should consult a healthcare professional. Elderly patients or those with impaired kidney function should have their dose carefully adjusted, and kidney function tests should be performed regularly. Avoid alcohol consumption while taking this medication, and if gastrointestinal discomfort or dehydration symptoms occur, temporarily discontinue use and consult with a healthcare professional. In case of overdose, seek appropriate medical treatment immediately, and this medication has not established safety for children, so it should not be used in that population. This medication may interact with other drugs, so it is essential to inform healthcare professionals of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and humidity; therefore, it should be stored in a tightly closed container. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage can help maintain the efficacy of the medication for a longer period.
Yellow, biconvex, oval controlled-release film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinpoong Pharmaceutical Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.